1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Proteasome Inhibitors Market: About this market
Proteasome inhibitors are used for the treatment of multiple myeloma. This proteasome inhibitors market analysis considers sales from VELCADE, KYPROLIS, NINLARO, and other products segments. Our analysis also considers the sales of proteasome inhibitors in Asia, Europe, North America, and ROW. In 2018, the VELCADE segment held the highest market share, which is expected to remain prevalent over the forecast period. The drug is the first proteasome inhibitor to receive approvals from the FDA and EMA. Moreover, the drug is the most effective in treating multiple myeloma. These factors will significantly help the VELCADE segment in maintaining its leading market position. Also, our global proteasome inhibitors report has observed market growth factors such as the huge unmet need, strong adoption rate, and growing incidence of myeloma. However, the threat from biologics, strong adverse effects, and slow regulatory approval may hamper the growth of the proteasome inhibitors industry over the forecast period.
Global Proteasome Inhibitors Market: Overview
Huge unmet need
There is a significant unmet treatment need for myeloma and a few solid tumor indications. Vendors are leveraging this situation and are focusing on developing therapeutics for the same. The market also has only a few approved therapies. As a result, there is significant scope for vendors to expand into the market. Therefore, the huge unmet need and the rising incidence of cancer will propel the growth of the global proteasome inhibitors market over the forecast period. The market is expected to record a CAGR of about 8% during the forecast period.
Expanded application
Apart from treating myeloma and solid tumors, proteasome inhibitor drugs are also being used to cure non-oncology conditions. For instance, ACU-D1 is a novel proteasome inhibitor that is proven to treat rosacea. The drug is in its second phase of clinical studies. There is ongoing research on expanding applications of proteasome inhibitor drugs to treat other conditions. This factor will have a positive impact on the overall market growth.
Competitive Landscape
With the presence of a few major players, the global proteasome inhibitors market is concentrated. This robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading proteasome inhibitors producers, which include Allergan Plc, Amgen Inc., Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the proteasome inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Proteasome inhibitors are used for the treatment of multiple myeloma. This proteasome inhibitors market analysis considers sales from VELCADE, KYPROLIS, NINLARO, and other products segments. Our analysis also considers the sales of proteasome inhibitors in Asia, Europe, North America, and ROW. In 2018, the VELCADE segment held the highest market share, which is expected to remain prevalent over the forecast period. The drug is the first proteasome inhibitor to receive approvals from the FDA and EMA. Moreover, the drug is the most effective in treating multiple myeloma. These factors will significantly help the VELCADE segment in maintaining its leading market position. Also, our global proteasome inhibitors report has observed market growth factors such as the huge unmet need, strong adoption rate, and growing incidence of myeloma. However, the threat from biologics, strong adverse effects, and slow regulatory approval may hamper the growth of the proteasome inhibitors industry over the forecast period.
Global Proteasome Inhibitors Market: Overview
Huge unmet need
There is a significant unmet treatment need for myeloma and a few solid tumor indications. Vendors are leveraging this situation and are focusing on developing therapeutics for the same. The market also has only a few approved therapies. As a result, there is significant scope for vendors to expand into the market. Therefore, the huge unmet need and the rising incidence of cancer will propel the growth of the global proteasome inhibitors market over the forecast period. The market is expected to record a CAGR of about 8% during the forecast period.
Expanded application
Apart from treating myeloma and solid tumors, proteasome inhibitor drugs are also being used to cure non-oncology conditions. For instance, ACU-D1 is a novel proteasome inhibitor that is proven to treat rosacea. The drug is in its second phase of clinical studies. There is ongoing research on expanding applications of proteasome inhibitor drugs to treat other conditions. This factor will have a positive impact on the overall market growth.
Competitive Landscape
With the presence of a few major players, the global proteasome inhibitors market is concentrated. This robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading proteasome inhibitors producers, which include Allergan Plc, Amgen Inc., Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the proteasome inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 07: MARKET SEGMENTATION BY PRODUCT
PART 09: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global proteasome inhibitors market pipeline: Overview
Exhibit 18: Global proteasome inhibitors market pipeline: Snapshot
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: VELCADE - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: VELCADE - Year-over-year growth 2019-2023 (%)
Exhibit 23: KYPROLIS - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: KYPROLIS - Year-over-year growth 2019-2023 (%)
Exhibit 25: NINLARO - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: NINLARO - Year-over-year growth 2019-2023 (%)
Exhibit 27: Other products - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Other products - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Allergan Plc - Vendor overview
Exhibit 54: Allergan Plc - Product segments
Exhibit 55: Allergan Plc - Organizational developments
Exhibit 56: Allergan Plc - Geographic focus
Exhibit 57: Allergan Plc - Segment focus
Exhibit 58: Allergan Plc - Key offerings
Exhibit 59: Allergan Plc - Key customers
Exhibit 60: Amgen Inc. - Vendor overview
Exhibit 61: Amgen Inc. - Business segments
Exhibit 62: Amgen Inc. - Organizational developments
Exhibit 63: Amgen Inc. - Geographic focus
Exhibit 64: Amgen Inc. - Key offerings
Exhibit 65: Amgen Inc. - Key customers
Exhibit 66: Celgene Corp. - Vendor overview
Exhibit 67: Celgene Corp. - Business segments
Exhibit 68: Celgene Corp. - Organizational developments
Exhibit 69: Celgene Corp. - Geographic focus
Exhibit 70: Celgene Corp. - Key offerings
Exhibit 71: Celgene Corp. - Key customers
Exhibit 72: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 73: Johnson & Johnson Services Inc. - Business segments
Exhibit 74: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 75: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 76: Johnson & Johnson Services Inc. - Segment focus
Exhibit 77: Johnson & Johnson Services Inc. - Key offerings
Exhibit 78: Johnson & Johnson Services Inc. - Key customers
Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 85: Validation techniques employed for market sizing
Exhibit 86: List of abbreviations
Exhibit 87: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- VELCADE - Market size and forecast 2018-2023
- KYPROLIS - Market size and forecast 2018-2023
- NINLARO - Market size and forecast 2018-2023
- Other products - Market size and forecast 2018-2023
- Market opportunity by product
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Expanded application
- Strategic alliances
- Special drug designations
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Allergan Plc
- Amgen Inc.
- Celgene Corp.
- Johnson & Johnson Services Inc.
- Takeda Pharmaceutical Co. Ltd.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global proteasome inhibitors market pipeline: Overview
Exhibit 18: Global proteasome inhibitors market pipeline: Snapshot
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: VELCADE - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: VELCADE - Year-over-year growth 2019-2023 (%)
Exhibit 23: KYPROLIS - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: KYPROLIS - Year-over-year growth 2019-2023 (%)
Exhibit 25: NINLARO - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: NINLARO - Year-over-year growth 2019-2023 (%)
Exhibit 27: Other products - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Other products - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Allergan Plc - Vendor overview
Exhibit 54: Allergan Plc - Product segments
Exhibit 55: Allergan Plc - Organizational developments
Exhibit 56: Allergan Plc - Geographic focus
Exhibit 57: Allergan Plc - Segment focus
Exhibit 58: Allergan Plc - Key offerings
Exhibit 59: Allergan Plc - Key customers
Exhibit 60: Amgen Inc. - Vendor overview
Exhibit 61: Amgen Inc. - Business segments
Exhibit 62: Amgen Inc. - Organizational developments
Exhibit 63: Amgen Inc. - Geographic focus
Exhibit 64: Amgen Inc. - Key offerings
Exhibit 65: Amgen Inc. - Key customers
Exhibit 66: Celgene Corp. - Vendor overview
Exhibit 67: Celgene Corp. - Business segments
Exhibit 68: Celgene Corp. - Organizational developments
Exhibit 69: Celgene Corp. - Geographic focus
Exhibit 70: Celgene Corp. - Key offerings
Exhibit 71: Celgene Corp. - Key customers
Exhibit 72: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 73: Johnson & Johnson Services Inc. - Business segments
Exhibit 74: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 75: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 76: Johnson & Johnson Services Inc. - Segment focus
Exhibit 77: Johnson & Johnson Services Inc. - Key offerings
Exhibit 78: Johnson & Johnson Services Inc. - Key customers
Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 85: Validation techniques employed for market sizing
Exhibit 86: List of abbreviations
Exhibit 87: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
The following companies are recognised as the key players in the global proteasome inhibitors market: Allergan Plc, Amgen Inc., Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the expanded application.”
According to the report, one of the major drivers for this market is the huge unmet need.
Further, the report states that one of the major factors hindering the growth of this market is the threat from biologics.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the expanded application.”
According to the report, one of the major drivers for this market is the huge unmet need.
Further, the report states that one of the major factors hindering the growth of this market is the threat from biologics.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Allergan Plc
- Amgen Inc.
- Celgene Corp.
- Johnson & Johnson Services Inc.
- Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
LOADING...
